Conference abstractPublished 27 Jul 2015
Safety study of intravenously administered human cord blood stem cells in the treatment of symptoms related to chronic inflammation
Blue Horizon International, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Stem cell research plays an important role in orthopedic regenerative medicine today. Arthritis literally means "inflammation of a joint." Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy of symptoms related to chronic inflammatory diseases. Blue Horizon Stem Cell Therapy Program is a leading provider of adult and children’s stem cell therapies. The purpose of this study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs), and secondly, to evaluate effects on biomarkers associated with chronic inflammation. Our study of blood test markers of 9 patients with chronic inflammation before and within three months after MSCs treatment demonstrates that there is no significant changes and MSCs treatment was safe for the patients. Analysis of different indicators of chronic inflammation included in initial, 24-hours, two weeks and three months protocols showed that stem cell treatment was safe for the patients. Further close monitoring and inclusion of more patients are necessary to fully characterize the advantages of UC-MSCs application in treatment of symptoms related to chronic inflammation.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGenetics & Molecular Biology
- SubjectHaematology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Brian Mehling”